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Abstract
Throughout history, Mycobacterium tuberculosis (MTB) has killed more people than any
other infectious agent, while Mycobacterium leprae is an ancient human pathogen that
still causes disease today. Each has developed drug resistance, thus the discovery of
potential novel antibiotic targets is essential. The diadenosine polyphosphatases
(ApnAases) / mRNA decapping enzymes of the Nudix hydrolase superfamily have been
found to be essential for a number of pathogens (Bartonella bacilliformis, Legionella
pneumophila) to invade human host cells, a process often essential for pathogenesis, and
thus potential novel drug targets. There are two ApnAases in MTB: Rv2985 and Rv3908
and two corresponding orthologs in M. leprae: Ml1682 and Ml2698. Our laboratory has
cloned, expressed, purified, and characterized Rv2985. Here, I describe the subcloning,
expression, and partial purification of Rv3908, Ml1682, and Ml2698. The three genes
were each subcloned to incorporate a His•Tag onto the N-terminus of each protein. Each
His•Tagged protein was expressed and purified via Ni2+ affinity chromatography. The
two ApnAases from M. leprae are fairly insoluble and thus a number of experiments were
carried out aimed at increasing Ml1682’s solubility: varying expression temperature,
Isopropyl-β-D-thiogalactopyranoside (IPTG) concentration, or time of expression after
induction; the use of the chaperone GroESL, codon+ E. coli strain Rosetta(DE3),
minimal media; or inclusion of glycylglycine. These standard methods of solubilization
did not improve the solubility of this ApnAase from M. leprae, and thus other methods to
improve solubility will need to be determined before we purify and characterize these
enzymes. Rv3908 is more soluble, and is ready to purify and characterize.
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1. Introduction
1.1 Leprosy
1.1.1 Definition of Leprosy
Leprosy is a rare but painful chronic infectious disease caused by Mycobacterium
leprae and Mycobacterium lepromatosis. Though leprosy is not highly contagious, it does
cause serious health issues for those who are infected. The bacteria seek out the coldest
place they can find in the human body such as eyes, face, hands, and feet, affecting the
eyes, nasal mucosa, skin, and peripheral nervous system,1,2 thus leading to vision
problems, skin lesions, and the loss of extremities. Leprosy is characterized by the
formation of nodules, ulceration, and the loss of sensation that leads to deformities,
wasting of muscle, and paralysis.3 The exact routes of transmission are unknown,
however it is believed that leprosy is mainly spread by nasal droplets or secretions from
infected person to healthy person4 or from infected armadillo to healthy person.5

1.1.2 Leprosy History
Leprosy has existed since ancient times; it has been well documented by the oldest
civilizations of Egypt, India, and China. It was first described in Egyptian papyrus around
1550 B.C. and in Indian writings around 600 B.C.6 Greek records indicated that leprosy
appeared in Greece in 62 B.C. after the army of Alexander the Great came back from
India. At the same time in Rome, leprosy appeared after the return of Pompeii’s troops
from Asia Minor.6
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Throughout history, leprosy has been negatively judged and misunderstood. For a
long time leprosy was thought to be a hereditary disease. Daniel Cornelius Danielssen
(1815-1894), a Norwegian apothecary who studied leprosy and the skin doctor Carl
Wilhelm Boeck published a book that depicted the difference between leprosy and other
skin diseases with careful illustration and explanation.7 In their book, they described how
leprosy developed only in people whose immune systems were compromised, and it
seemed that the ability to resist the disease was genetically inherited. Since leprosy
showed up in those with a family history of leprosy, they thought leprosy was an
inherited disease. However, Danielssen’s protégé, Gerhard Henrik Armauer Hansen, did
not agree that leprosy was an inherited disease. To prove his hypothesis, Hansen obtained
a sample of tissue from a leprosy patient and examined it under the microscope, day after
day for more than one year until he saw a group of little sticklike things growing on one
of the sample plates. To prove that this tiny creature caused leprosy, he injected it into
rabbits, but the rabbits remained healthy. Then, he injected the microorganism into a
patient without her consent. The patient developed leprosy and thus sued Hansen. The
court removed Hansen from his post at the hospital. Nonetheless, Hansen continued his
work independently and eventually convinced the world that he found the causative agent
of leprosy and named leprosy Hansen’s disease. 7
Not only was leprosy mistakenly considered a hereditary disease prior to Hansen’s
work, but also a curse of sinners, a punishment from God. This was because the disease
could disfigure the hands and face, leaving a permanent mark, which many people
thought was a sign of sin. In Europe, from the time of the Crusaders (AD 1095-1272)
until the great plague epidemic of the fourteenth century, leprosy was widespread.7
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During that time, if someone had leprosy, they were taken to the church, forced to wear
special clothes or badges to distinguish them as unclean, and priests would stone them
and curse them to death.7 Leprosy patients had to carry a bell or strike sticks together to
warn others of their approach; they could not walk on narrow paths, could not speak
above a whisper, and could not bathe in the village stream. In some places, they were not
allowed in the markets or even in the town. In other regions, they were burned at the
stake or buried alive.7
Even after Hansen’s discovery that leprosy is a transmissible infectious disease,
leprosy patients were stigmatized. In the late nineteenth century, the Louisiana Leper
Home was established in Carville, Louisiana as the first leprosarium and refuge for
leprosy patients. Patients were isolated from the rest of the world, needed permission to
leave the leprosarium, and would be disgraced if they appeared in public.
Treatment for leprosy was limited. In the early twentieth century, leprosy patients
were treated with chaulmoogra nut oil, but this did not work for most patients. After the
discovery of antibiotics, the antibiotic dapsone was discovered and became an effective
drug treatment for leprosy starting in the 1950s. It worked wonderfully at first, until
antibiotic resistance developed to dapsone. In 1981, the World Health Organization
began recommending multi-drug therapy that finally made leprosy curable. Today,
although leprosy is curable, every two minutes someone around the world is diagnosed
with leprosy.8 The long fight is not over yet, and a leprosy vaccine is in the works.
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1.1.3 Leprosy: Types and Transmission
Prior to 2008, only one species of bacteria, Mycobacterium leprae, was known to
cause leprosy. In 2008, pathologist Xiang-Yang Han discovered that Mycobacterium
lepromatosis causes diffused lepromatous leprosy (DLL), the most severe form of
leprosy. DLL is mostly found in Mexico and the Caribbean.9
The mechanism of transmission for M. leprae is poorly understood. However the
nasal mucosa respiratory tract is the most likely point of entry. Prolonged contact or
overcrowding of leprosy patients with uninfected individuals will increase the risk of
leprosy infection. The bacteria can survive outside of the body from 36 hours to 9 days.
Skin transmission has never been proven.1 Recently, leprosy was found to be transmitted
through infected needles used in tattooing, mainly in India.10 Direct transmission from
mother to baby during pregnancy or childbirth is also possible.11 In the Old World, where
leprosy was first known, it was not known to be a zoonotic disease. However, leprosy has
since been found to be sustained in the armadillo population; hence, prolonged contact
with infected armadillo can cause leprosy infection in humans,5,12 since the pathogen
resides on the animal’s skin.

1.1.4 Leprosy: Classification and Clinical Features
Three main types of leprosy are known: lepromatous leprosy (LL), tuberculoid
leprosy (TL), and an intermediate state (Fig. 29, Appendix). The initial stage of the
disease (indeterminate cases) is easy to cure even if the clinical diagnosis is difficult. The
intermediate states are classified as borderline lepromatous (BL) or borderline
tuberculoid (BT). Both TL and BT are stable and rarely contagious. If the host’s immune
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system is strong, this type of leprosy may resolve spontaneously. However both LL and
BL can be dynamic, progressive, and infectious, and progression of the disease can cause
formation of nodules and papules with marked, diffused infiltration of the skin. This type
of leprosy involves more severe disability and nerve damage. The diagnosis of leprosy is
based on: hypopigmentation with loss of sensation, thickened peripheral nerves, and/or
acid-fast bacteria detected on skin smears or biopsy material.13
Leprosy is curable by a combination of first-line drugs. First-line drugs include
rifampicin (inhibits RNA synthesis), dapsone, and clofazimine (mechanisms are poorly
known) (Fig. 30, Appendix). Second-line drugs (minocycline, ofloxacin (floroquinolone),
and clarithromycin) are available if bacteria become resistant to first-line drugs. Although
leprosy is curable with antibiotics and the disease is rare in United States with only 100200 new cases each year, there are still hundreds of thousands of new cases reported
worldwide annually.12

1.1.5 Leprosy Genomics and Pathogenesis
Mycobacteria are commonly found in the soil and water, and many are nonpathogenic to humans, whereas a few of them are pathogens to humans and animals
(M. leprae, M. lepromatosis and M. tuberculosis). Mycobacteria are known for their slow
growth with doubling times of approximately 24 hours for M. tuberculosis and 14 days
for M. leprae. Hence, it is very difficult to culture M. leprae in vitro, and currently there
is no method to do so; however, the genome of M. leprae has been completely
sequenced.14 Phylogenetic studies of M. leprae and M. lepromatosis showed that they
came from a common ancestor approximately ten million years ago. Before the
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divergence, their ancestor had undergone a massive reductive evolution that caused
inactivation of approximately forty percent of all the genes in its genome (~2000 genes)
that are no longer required in highly specialized niches;14,15 the remaining genes are a
minimal gene set necessary for survival, infection, and pathogenesis.

1.2 Tuberculosis
1.2.1 Definition of Tuberculosis
Tuberculosis (TB) is an infectious disease that is mainly caused by Mycobacterium
tuberculosis (MTB). It typically infects the lungs, resulting in chest pain, bloody sputum,
and often death. MTB can also affect the brain and spine.16 Its route of transmission is
through air droplets from the sputum from the infected lungs (Fig. 31, Appendix). The
risk of transmission is based on the degree of exposure (proximity and time) and how
vulnerable an exposed person is (people with weakened immune systems tend to be at
increased risk of infection).17
	
  
1.2.2 History of Tuberculosis
TB is an ancient disease, documented in Egypt more than 5000 years ago, in India
3300 years ago, and in China 2300 years ago.18 TB has plagued humankind throughout
history; prior to antibiotics patients could not be cured. Even diagnosing TB was a
challenge. Physicians developed different tests to confirm TB. The ancient Greeks
developed tests to analyze what the tubercular patient coughed up; they had the patient
spit into a copper vessel filled with seawater and watched the sputum’s behavior or they
dripped the sputum on hot coals and smelled for “rotten meat”.7
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Diagnosis methods improved in 1761 when Leopold Auenbrugger invented
percussion. This method allowed a physician to put his ear to a patient’s chest, gently tap
the chest, and listen. A dull vs. a hollow sound indicated that the lungs were not healthy
and that the person might have TB. René Laënnec improved percussion by using a
stethoscope.19 In 1895, Wilhelm Roentgen developed the use of X-rays, and this method
is still in use today for early diagnosis of infected patients.20
Since there was no cure for TB before the discovery of antibiotics, people who were
diagnosed with TB would try everything they could think of to cure themselves, which
included a lot of seemingly odd treatments, but ultimately the treatments that appeared to
work were most likely boosting the immune system. Facilities opened where only people
with TB could go to attempt to be cured. These sanatoria, usually located in the
countryside or mountains,7 allowed patients to get plenty of fresh air, sun, rest, and
nutritious food, all things now known to boost the immune system. An additional benefit
was that they were isolated from uninfected people; they would stay at the sanatorium
until they were cured or died from the disease.21 Unfortunately, sanatoria became very
crowded and the number of people infected with TB greatly outnumbered those who
could be admitted.
The bacterium that causes TB was isolated and discovered by Robert Koch in 1882.7
After isolating bacteria from the lungs of TB patients, he tried staining the cultures. It
was good fortune that he used an old methylene blue dye contaminated with ammonia,
which allowed the dye to enter the cells by destroying TB’s protective coat. In this way
Koch confirmed that isolated stained rod microorganisms were the cause of TB.
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In 1921, French scientists Albert Calmette and Camille Guérin developed a vaccine
against TB, known as BCG (Bacillus Calmette-Guérin) vaccine.22 More recently, it has
been discovered that the vaccine is only eighty percent effective in preventing TB in
children, and not very effective in adults.23
In 1944, Selman Waksman and Albert Schatz discovered streptomycin, the first
antibiotic effective against TB.24, 25 This was a miracle drug, as it was the first truly
effective cure for TB. Because of streptomycin’s great success, many antibiotics were
developed in the 1940s and 1950s, the most notable being isoniazid and rifampin.18 There
was a sharp decline in TB between 1953 and 1987, with the number of TB cases
dropping by more than seventy percent in the United States due to the discovery and
surge in antibiotics.7, 26 Unfortunately, resistance of TB to streptomycin started to develop
within months of its discovery, and resistance to other antibiotics followed within years
of their discovery. TB cases rose dramatically due to both resistance to antibiotics and the
emergence of HIV-infections between the late 1980s and 1992.27 A novel program
developed in the early 1990s, Directly Observed Therapy Short-Course (DOTS),27, 28 has
become an effective treatment against TB and is still used today. This program is time
consuming and expensive because it involves health care workers physically watching
patients taking their TB medications. However, it works, and studies have shown that
eighty percent of TB patients in Africa and India have been cured using DOTS.7

1.2.3 Latent Infection of TB and MTB Life Cycle
TB can exist in two different forms in the human body: as a latent infection or as an
active infection. A latent infection of TB is shown in Fig. 31 (Appendix); MTB can be
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found inside granulomas for years, and individuals show no symptoms of TB, as the
immune system keeps the MTB in check and represses its multiplication and spread
inside the body.
The bacteria first enter the body by inhalation of droplets that contain MTB. When
the bacterium reaches the alveoli of the lung, it is recognized and taken up by
phagocytosis (macrophages). The macrophages then move to the surrounding tissue in
the epithelial layer causing a local immune response. B-cells and T-cells quickly arrive
trying to eliminate the bacteria, which causes the formation of a granuloma.29 The
infected macrophages reside in the center of the granuloma that has ingested the MTB.
As seen in Fig. 31 (Appendix) these infected cells are surrounded by other immune cells
such as lymphocytes and other macrophages. These immune cells in granuloma
eventually develop a fibrous material that envelops the mass of immune cells. This is its
latent stage, if the bacteria stay dormant inside of the granuloma. Otherwise, the
granuloma lose vasculature, causing cell death and rupture of the granulomas, thus
allowing the bacteria to multiply and be released into the airways where it can now infect
other people.30

1.2.4 Active Infection of TB and Its Symptoms
Patients with latent TB cannot transmit the disease to others, but it can become
active (Fig. 31, Appendix) if the individual becomes immunocompromised:
AIDS,29,30,32,33 age,31 malnutrition,34 and diabetes mellitus35 all suppress the immune
system. Individuals with AIDS are 30 times more susceptible to becoming infected with
TB. In active TB, MTB multiplies inside of the granuloma (Fig. 31, Appendix) and
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causes the granuloma to rupture at which point the person infected will start to show
symptoms of the disease: chest pain, weakness, unintentional weight loss, fever, and
cough.36 Because many of TB symptoms are similar to those of other diseases, such as
influenza or the common cold, it can be difficult to diagnose. The main telltale sign of
active TB is the coughing up of blood, but by that point, TB is usually quite advanced.

1.2.5 Mechanisms of Drug Action and Drug Resistance
Despite the availability of the BCG vaccine and an effective DOTS program, TB has
been the leading cause of death due to infectious disease throughout history, and has
killed more than a billion people in the past two hundred years alone29 (Fig. 32,
Appendix). Two main reasons for the increase in TB in more recent years and what
makes it so difficult to eliminate are: the deadly synergy with the human
immunodeficiency virus33 (HIV) and the development of drug resistant strains of TB.
Genomic studies of various MTB strains show that there are three types of drug
resistant strains of TB: multidrug-resistant TB (MDR-TB), extensively or extremely
drug-resistant TB (XDR-TB), and totally drug-resistant TB (TDR-TB). MDR-TB is
resistant to the two most commonly used first-line drugs, isoniazid and rifampin, in the
current five-drug regimen (Fig. 30, Appendix). More than eighty percent of MDR-TB
patients died in the late 1980s and early 1990s in North America and Europe.37 MDR-TB
is treated with second-line drugs (capreomycin, amikacin, and kanamycin) (Fig. 30,
Appendix), which are toxic with dangerous side effects. XDR-TB is resistant to both
isoniazid and rifampin with any fluoroquinolone, and at least one of the second-line
drugs.38 With resistance to so many antibiotics, treatment is challenging. TDR-TB is
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resistance to all currently available antibiotics. Since there is no treatment, active
TDR-TB is always lethal. So far, there have been only a few cases of TDR-TB. However
if TDR-TB spreads, we could be facing a new pandemic of untreatable TB.39

1.2.6 Discovery and Characterization of Novel Potential Antibiotic Targets
As can be seen, especially for MTB, antibiotic drug resistance is a serious problem.
Thus, it is essential to discover novel potential antibiotic targets and to develop drugs
against these targets. Our research pertains to the discovery and characterization of new
potential drug targets in the important human pathogens M. leprae and MTB. By
studying enzymes of a particular protein superfamily, we increase the probability of
determining the activity of these enzymes. We have chosen to focus on the Nudix
hydrolases, as discussed below.

1.3 Nudix Hydrolases
1.3.1 Definition
The Nudix hydrolases are a superfamily of enzymes found in all three domains of
life: archaea, prokaryotes, and eukaryotes. They hydrolyze substrates with the general
structure of a nucleoside diphosphate linked to some moiety, X (Nudix) and almost
always yield NMP and X-P as products. The general reaction is:
𝐍 − 𝐏 − 𝐏 − 𝐗   +    𝐇𝟐 𝐎   →   𝐍𝐌𝐏   +   𝐗 − 𝐏	
  	
  

	
  

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  Eq. 1

Nudix hydrolase superfamily enzymes are typically small single domain proteins
(16-21 kDa, 130-200 residues). They are identified by the highly conserved 23-amino
acid signature sequence (Nudix box), GX5EX7REUXEEXGU, where U is a bulky
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aliphatic amino acid (I, L, or V), and X is any amino acid. The consensus sequence
creates a loop-helix-loop structural motif, and the glutamates in the core of the motif
(REUXEE), play an essential role in binding of divalent cations (usually Mg2+).40
The first characterized enzyme of the Nudix hydrolase superfamily was MutT from
Escherichia coli (E. coli). Disruption of mutT causes a 1,000-10,000 fold increase in the
spontaneous mutation frequency due to AT:CG transversions.41 One hypothesis for how
MutT prevents mutations is its hydrolysis of the reactive oxygen species 8-oxo-dGTP to
prevent its incorporation into DNA. Initially scientists thought this might be an
antimutator family, but it was quickly discovered that only MutT and its orthologs
prevent mutations.

1.3.2 Substrate Specificity and Enzyme Function
The Nudix hydrolase superfamily is composed of enzymes with a wide array of
substrate specificities. Nudix hydrolases recognize and cleave a specific group of
substrates such as: (d)NTPs (Eq 2-4), nucleotide sugars (Eq 5-7), diadenosine
polyphosphates (ApnA) (Eq 8-10), or coenzyme A (Eq 11). However, some Nudix
hydrolases can have broad substrate specificity; YZGD has the broadest substrate
specificity of all the Nudix hydrolases that have been characterized, hydrolyzing ADP-x,
CDP-x, and TDP-x substrates equally well, and even hydrolyzing UDP-x and GDP-x to a
lesser extent. The only Nudix substrates that YZGD does not cleave are (d)NTPs,
ApnA’s, and coenzyme A.42
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𝟖𝐨𝐱𝐨 𝐝𝐆𝐓𝐏   +   𝐇𝟐 𝐎   →    𝟖𝐨𝐱𝐨 𝐝𝐆𝐌𝐏   +   𝐏𝐏𝐢

Eq. 2

                                                        𝐝𝐀𝐓𝐏   +  𝐇𝟐 𝐎   →   𝐝𝐀𝐌𝐏   +   𝐏𝐏𝐢

Eq. 3

                                                    𝐂𝐓𝐏   +  𝐇𝟐 𝐎     →   𝐂𝐌𝐏       +   𝐏𝐏𝐢

Eq. 4

        𝐀𝐃𝐏 − 𝐫𝐢𝐛𝐨𝐬𝐞   +    𝐇𝟐 𝐎   →   𝐀𝐌𝐏     +   𝐫𝐢𝐛𝐨𝐬𝐞 − 𝟓 − 𝐏

Eq. 5

𝐆𝐃𝐏 − 𝐦𝐚𝐧𝐧𝐨𝐬𝐞 + 𝐇𝟐 𝐎 →   𝐆𝐃𝐏       +   𝐦𝐚𝐧𝐧𝐨𝐬𝐞

Eq. 6

  𝐔𝐃𝐏 − 𝐠𝐥𝐮𝐜𝐨𝐬𝐞     + 𝐇𝟐 𝐎   →   𝐔𝐌𝐏   +   𝐠𝐥𝐮𝐜𝐨𝐬𝐞 − 𝟏 − 𝐏

Eq. 7

                                            𝐀𝐩𝟒 𝐀   + 𝐇𝟐 𝐎   →   𝐀𝐌𝐏   +   𝐀𝐓𝐏

Eq. 8

                                              𝐀𝐩𝟓 𝐀 + 𝐇𝟐 𝐎   →   𝐀𝐃𝐏   +   𝐀𝐓𝐏

Eq. 9

                                              𝐀𝐩𝟔 𝐀 + 𝐇𝟐 𝐎 →   𝐀𝐓𝐏     +   𝐀𝐓𝐏

Eq. 10

′

                                                                    𝐂𝐨𝐀 + 𝐇𝟐 𝐎   →    𝟑 , 𝟓

′

− 𝐀𝐃𝐏   +  𝟒′ − 𝐩𝐡𝐨𝐬𝐩𝐡𝐨𝐩𝐚𝐧𝐭𝐞𝐭𝐡𝐞𝐢𝐧𝐞  

Eq. 11	
  

Due to their versatile substrate preferences, Nudix hydrolases are suggested to be
involved in a variety of different metabolic pathways. Bessman defined the Nudix
hydrolases as having a common “housecleaning” function, “cleansing potentially
hazardous

materials,

or

preventing

the

unbalanced

accumulation

of

normal

metabolites.”41

1.3.3 The Nudix Hydrolases from MTB and M. leprae
There are eleven potential Nudix hydrolases in MTB, as determined by their Nudix
signature sequence. The O’Handley lab has been systematically cloning, expressing, and
characterizing these enzymes. Ten have been cloned, six express to produce obvious
bands of overexpressed protein on SDS PAGE, but the enzymatic activity has only been
determined for four: two ApnAases, one (d)CTPase, and one ADP-ribose hydrolase, (see
Table I). Five of the MTB Nudix hydrolases have highly conserved homologs in
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M. leprae with E values of E-107 to E-144, and five have homologs in M. leprae with E
values of E-2 to E-10, (see Table II).
Note the two diadenosine polyphosphatases in MTB and the two corresponding
orthologs in M. leprae (Fig. 2 and 3). If an organism has two proteins with similar
activity and function, this is an indication that the activity is probably important for the
organism’s survival. M. leprae has gone through significant reductive evolution;14, 43 if a
protein / protein function exists in M. leprae, this is another indication that the activity is
probably important for the M. leprae’s survival, as it has jettisoned many proteins and
activities through reductive evolution.

Table I: Nudix hydrolases from MTB
Protein	
  

Nudix	
  Sequence	
  

Cloned	
  	
   Expressed	
   Substrate(s)	
  	
  

Rv2985	
  
Rv3908	
  
Rv1160	
  
Rv1700	
  
Rv1593	
  
Rv3733	
  
Rv413	
  
Rv1745	
  
Rv3199	
  
Rv3672	
  
Rv2609	
  

GKVDPGETAPVGAVREILEETGH
GHEILGETAEQTAIREVAEERGI
GKVAAGETERAALARELAEELGL
GLLDVAGEPPHLTAARELREEVGL
GRLRNDEDMTSSVRRQLAEKVDL
GEYTGGEDPWLAARREFSEEIGL
GARDSHETPEQTAVRESSEEAGL
GHPLPGESLPGAIRRRLAAELGL
GQVRPGERLAQAAARELAEETGL
GCCPADDGPVATALREANEETGI
GQVRPGERLAQAAARELAEETGL

+	
  
+	
  
+	
  
+	
  
+	
  
+	
  
+	
  
+	
  
+	
  
+	
  
-‐	
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+	
  
+	
  
+	
  
+	
  
+	
  
+	
  
-‐	
  
-‐	
  
-‐	
  
-‐	
  
-‐	
  

ApnA	
  
ApnA	
  
(d)	
  CTP	
  
ADP-‐ribose	
  
-‐	
  
-‐	
  
-‐	
  
-‐	
  
-‐	
  
-‐	
  
-‐	
  

Table II: Nudix hydrolases from M. leprae
MTB Protein
M. leprae Orthologa
Predicted Substrate(s)b
Rv2985
ApnA
1 × E-130
-107
Rv3908
ApnA
1×E
-4
Rv1160
(d)CTP
2×E
-5
Rv1700
ADPribose
4×E
-114
Rv1593
GDPmannose
1×E
-2
Rv3733
3×E
Rv413
(d)CTP
9 × E-5
Rv1745
Rv3199
NADH
3 × E-3
-114
Rv3672
CoA
1×E
-144
Rv2609
1×E
a
: “the Expectation value represents the number of different alignments with scores
equivalent to or better than S that is expected to occur in a database search by chance.
The lower the E value, the more significant the score and the alignment.”44
b:
These predictions came from the entrez report pages for the MTB homologs.
	
  
1.3.4 Diadenosine Polyphosphatases
	
  Diadenosine polyphosphatases, ApnAases where n≥4, are Nudix hydrolases found in
bacteria, plants, and animals that cleave diadenosine polyphosphates (ApnA) into two
products as depicted in equations 8-10 in section 1.3.2. Substitution always occurs on the
fourth phosphate δP (for n≥4) with ATP as the leaving group. The general role of
diadenosine polyphosphatases is to regulate the cellular levels of diadenosine
polyphosphate signaling molecules.
Phenotype studies of knockout mutants showed that diadenosine polyphosphatases
are involved in the invasion process of human host cells by various pathogens. The
Ap4Aases from Bartonella bacilliformis (the cause of Oroya fever) and Helicobacter
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pylori (a cause of stomach ulcers) are involved in and required for the pathogens’ ability
to invade human erythrocytes45 and the gastric system,46 respectively. ApnAase was
determined to be a virulence factor in Legionella pheumophila.47 ApnAase from
Rickettsia prowazekii, the causative agent of epidemic typhus, was found to be involved
in invasion of the host’s endothelia cells.48
Diadenosine polyphosphatases are also found in MTB (Rv2985 and Rv3908) and
M. leprae (Ml1682 and Ml2698). Rv2985 has been cloned, expressed, purified, and
characterized previously by others in the O’Handley lab, therefore the main focus of this
thesis project is on Rv3908 and the two orthologs from M. leprae. If these enzymes are
involved in invasion and thus in virulence, similar to the orthologs discussed in the above
paragraph, these enzymes could be novel antibiotic targets in MTB and M. leprae.
Alignments of these ApnAases are shown in Fig. 1-3, where the following amino
acid groupings are designated as similar amino acids: A/G, I/L/V, S/T, F/W/Y, D/E,
K/R/H, and N/Q.
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Figure 1:	
  Clustal alignment of Nudix hydrolase diadenosine polyphosphatases. Identical
amino acids are denoted by “*” and similar amino acids are denoted by “•”.
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Figure 2: Clustal alignment of ApnAase/mRNA decapping orthologs Rv2985 in
M. tuberculosis and Ml1682 in M. leprae. 72% of the amino acids are identical and
denoted by “*” while 76% of the amino acids are similar and denoted by “•”.
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Figure 3: Clustal alignment of ApnAase/mRNA decapping orthologs Rv3908 in
M. tuberculosis and Ml2698 in M. leprae. 79% of the amino acids are identical and
denoted by “*” while 83% of the amino acids are similar and denoted by “•”.

1.3.5 mRNA Decapping Enzyme
In both prokaryotes and eukaryotes, DNA is transcribed into messenger RNA
(mRNA) before it is translated into protein. In eukaryotes, the transcribed mRNA is
processed prior to translation. mRNA processing includes the addition of a 5’ 7-methyl
guanosine cap (Me7Gp3), addition of a poly-A tail at the 3’ end, and mRNA splicing to
remove non-coding introns. The Me7Gp3 capping protects the mRNA chain from
degradation by nucleases. Hence, the first step of degradation of mRNA is to remove the
methylated cap (decapping).
Degradation of mRNA is an essential process in eukaryotic cells to control gene
expression. The mRNA decapping enzymes remove the methylated cap to expose a
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monophosphorylated 5’ end on the mRNA.49 These eukaryotic enzymes that
hydrolytically decap the 5’ end of capped mRNA were found to contain the 23-residue
Nudix signature sequence. The catalytic reaction is shown below (eq. 12).50
                                        𝐌𝐞𝟕 𝐆𝐩𝟑 − 𝐑𝐍𝐀 + 𝐇𝟐 𝐎 → 𝐌𝐞𝟕 𝐆𝐃𝐏 + 𝐩 − 𝐑𝐍𝐀

Eq. 12

More interestingly, several prokaryotic diadenosine polyphosphatases have recently
been discovered to also act as mRNA decapping enzymes to remove pyrophosphate from
the 5’ termini of mRNAs. Thus, these activities suggest both ApnA’s and mRNAs are
biologically relevant substrates for these ApnAase mRNA decapping enzymes, and
currently it is not known which activity or if both activities are involved in the invasion
process.51

1.3.6 Rv2985 ApnAase from MTB
Rv2985 has been previously cloned, expressed, purified, and characterized in the
O’Handley lab. The gene rv2985 was successfully cloned into the plasmid pET11b to
create pETrv2985, and successfully subcloned into the plasmid pET19b to create
pET19rv2985, which placed a His•Tag at the N-terminal end of the expressed protein.
Each was transformed into Escherichia coli (E. coli) DH5α for storage and E. coli
BLR(DE3) for expression.
Untagged Rv2985 protein was purified and characterized; however, for easier
purification and higher yield of purified protein, Rv2985(HT) was also purified and
characterized. Rv2985(HT) was expressed at 15 °C in E. coli BLR(DE3) using isopropyl
β-D-1-thiogalactopyranoside (IPTG) to induce protein production. The cells were
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harvested and ruptured by sonication. The sonicated supernatant was purified via Ni2+
affinity chromatography followed by size exclusion chromatography (see Fig. 4).
Both the untagged protein and the His•Tagged protein gave identical results upon
characterization. Rv2985 is a diadenosine polyphosphatase with maximal activity on
Ap6A (see Table III). Optimal activity was achieved in the pH range of 8.5-9.0 and in the
presence of 5 mM Mg2+. Zn2+, Mn2+, and Co2+ yielded 21%, 6%, and 4% as much
activity (as with 5 mM Mg2+), respectively, while Ca2+ yielded no activity. Rv2985
always attacks the fourth phosphorous from one of the adenosines to yield ATP and
either AMP, ADP, or another ATP depending on whether the substrate is Ap4A, Ap5A, or
Ap6A, respectively (see Fig. 5). Rv2985 has also been determined to be a mRNA
decapping enzyme by our collaborators, Sandra Gabelli and Mario Amzel at Johns
Hopkins University (see Fig. 6).
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Figure 4: Expression and purification of Rv2985(HT). Lane1: sonicated supernatant;
Lanes 2&3: purified Rv2985(HT) after Ni2+ affinity chromatography, dialysis, and
concentration; Lane 4: Molecular Weight Markers (MWMs). (Unpublished results,
O’Handley et al.)
	
  
Table III: Substrate Specificity and Kinetics of Rv2985(HT).
Substrate
Ap6A
Ap5A
Ap4A

	
  

kcat (s-1)
74.41
27.09
31.81

Km (M)
1.78×10-3
1.02×10-3
1.22×10-3
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kcat/Km (M-1s-1)
4.18×104
2.66×104
2.61×104

A.
	
  

B.
	
  

	
  

Figure 5: Reactions of the ApnA’s with Rv2985. A. HPLC chromatograms showed that
for the substrates Ap4A, Ap5A, and Ap6A, the products were ATP and either AMP, ADP,
or ATP, respectively. ATP is always one of the products. B. 31P NMR showed the same
products as HPLC. Additionally, when the reactions were carried out in H218O, the 18O
was transferred to AMP (for the reaction with Ap4A) and ADP (for the reaction with
Ap5A) indicating that attack by H2O is always at the fourth phosphorus from one of the
adenosines. (Unpublished results, O’Handley et al.)
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Figure 6: mRNA decapping assay. Rv2985 removed the 5’ 32P-labeled end of
triphosphate capped mRNA releasing radioactive pyrophosphate. Nudt1 (Human mutT 8oxo-dGTPase) was used as a negative control as it does not decap mRNA. (Unpublished
results, Gabelli and Amzel, in collaboration)

1.4 Methodology
1.4.1 Subcloning
For this thesis, genes were subcloned from pET11b into pET19b. Both plasmids
contain a T7 lac promoter for overexpression. The T7 lac promoter has a lac operator
sequence situated downstream from the promoter region.52 The lac repressor binds to this
region and inhibits transcription, thus reducing basal expression. A similar lac promoter
controls transcription of the T7 RNA polymerase that is encoded in (DE3) strains of
E. coli and both are inducible by IPTG. The structure of IPTG is similar to allolactose, a
natural inducer for the lac promoter. pET19b also contains a sequence that codes for a
string of 10 histidines to create a His•Tag on the N-terminal end of the protein.53 A
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schematic of the pET19b plasmid is shown in Fig. 7. The pET plasmids contain NdeI and
BamHI restriction sites, which can be utilized for subcloning as depicted in Fig. 8.

Figure 7: pET19b containing a T7 lac promoter, a His•Tag coding sequence, EcoRV,
NdeI, and BamHI restriction sites.
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Figure 8: ml1682 subcloned into pET19b. ml2698 and rv3908 were subcloned identically.

1.4.2 Overexpression and Purification
The procedure for overexpression and purification of protein is shown on Fig. 9.
Proteins are overexpressed by induction with IPTG. Sonication lyses cells by high energy
sound waves. Ni2+ affinity chromatography resin binds His•Tagged proteins tightly
through the imidazole side chains of histidine forming complexes with the Ni2+ of the
column, allowing all other proteins to flow through the column. Increasing concentration
of imidazole allows the imidazole to outcompete with the His•Tagged proteins for the
Ni2+ of the resin. (Fig. 33, Appendix).

	
  

26	
  

Figure 9: Schematic for Ml1682(HT), Ml2698(HT), and Rv3908(HT) expression and
purification.

	
  

Dialysis is used to remove the free imidazole from the His•tagged protein sample.
Dialysis separates small molecules from macromolecules based on their molecular size.
The membrane of the dialysis cassette allows small molecules such as imidazole to
diffuse through the membrane, retaining the large macromolecules in the cassette.
Concurrently, the new buffer outside the dialysis cassette can diffuse into the cassette
through the membrane.

1.4.3 Solubilization Experiments
Prokaryotic expression systems, especially E. coli, have been exploited for the
production of a wide range of recombinant proteins in the last three decades. E. coli cells
are convenient hosts for the expression of foreign proteins because they have a short
doubling growth rate, require inexpensive growth conditions, and offer a simple process
to scale up. However, two main disadvantages of using E. coli cells are: expression can
be low due to rare codon usage and they can produce inactive insoluble protein due to the
formation of inclusion bodies. A number of current strategies have been developed to aid
in expression of soluble protein.
Protein expression at low temperatures slows down cell growth and protein
expression allowing more time for the protein to fold, increasing the probability of proper
folding.54 A change in media composition is another technique to obtain soluble protein.
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Cells grow slower in M9 minimal media,55 thus as with lower temperatures, the proteins
express and fold more slowly. The addition of glycylglycine into rich media enhances
production of soluble proteins by also slowing down cell growth and allowing more time
for the expressed proteins to fold properly.56 Co-expression with the chaperone
GroEL-GroES can increase solubility of expressed proteins, because molecular
chaperones assist the folding of polypeptides.57, 58
Most amino acids are encoded by more than one codon and each organism has a
codon bias. When the genes that encode foreign proteins contain “rare” codons for
E. coli, E. coli does not produce as much aminoacyl tRNA for that codon, leading to
lower translation rates and thus lower protein expression. The E. coli strain Rosetta(DE3)
overexpresses these “rare” tRNAs, and thus allows for more efficient translation,
resulting in better expression and the production of more soluble protein.59
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2. Materials and Methods
2.1 Subcloning of ml1682, ml2698, and rv3908 into pET19b
2.1.1 Plasmid Midipreps
Prior to this work, others in the O’Handley lab cloned ml1682, ml2698, and rv3908
into pET11b to create pETml1682, pETml2698, and pETrv3908, respectively. pET19b is
a plasmid containing a nucleotide sequence that codes for a string of 10 histidines at the
N-terminal end of a protein. E.coli DH5α cells containing pET19b, pETml1682,
pETml2698, or pETrv3908 were each grown in separate 50 mL Luria-Bertani (LB) media
with 0.1 mg/mL ampicillin at 37 °C with shaking for approximately 16 hours. The cells
were harvested by centrifugation at 14,000 RCF (relative centrifugal force) for 2 minutes
at room temperature. Harvested cells were treated with 100 µL solution I containing
50 mM glucose, 25 mM Tri•HCl (pH 8.0), and 10 mM EDTA to resuspend the cells.
200 µL solution II containing 0.2 M sodium hydroxide and 1% SDS was added to rupture
the cells. 150 µL solution III containing 3 M potassium and 5 M acetate was used to
precipitate

E.coli

chromosomal

DNA,

leaving

plasmid

DNA

in

solution.

DNase-free bovine pancreatic RNase A (Sigma) in TE buffer (10 mM Tris•HCl (pH 8.0),
1 mM EDTA) was added to the supernatant for a final concentration of 50 µg/mL
RNase A, and this was incubated at 37 °C for 30 minutes. Proteins were denatured and
removed using phenol:chloroform (1:1) and chloroform extractions. The plasmid DNA
was precipitated with 70% ethanol by freezing the solution and centrifugation at
14,000 RCF at 4 °C for 30 minutes. The pellet was washed with ice-cold 70% ethanol
and dried using vacuum centrifugation. The pellet was dissolved in cold sterile water.
The plasmid DNA was treated with 13% polyethylene glycol (PEG) and 5 M sodium
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chloride solution on ice for approximately 18 hours to remove tRNAs from the sample.
The sample was centrifuged at 14,000 RCF at 4 °C for 30 minutes, and the pellet
containing the plasmid was washed with 70% ice-cold ethanol. Pellets were resuspended
in cold sterile water. The DNA concentration was determined at 260 nm on a UV-Vis
spectrophotometer. The plasmids were analyzed further by 0.7% agarose gel
electrophoresis.

2.1.2 Restriction Enzyme Digests and Purification of Digested Gene and Digested
Plasmid
The restriction enzymes, NdeI and BamHI-HF endonucleases (New England
Biolabs) were used in a double-digest to excise the ml1682, ml2698, or rv3908 genes
from the pETml1682, pETml2698, or pETrv3908 plasmids, respectively. The pET19b
plasmid was also digested with the same restriction enzymes. The efficiency of the
digests was verified by also treating pET19b plasmid with each of the restriction enzymes
separately. Samples were analyzed by 0.7% agarose gel electrophoresis. The digests were
incubated at 37 °C for 2 hours total; NdeI endonuclease was added to each sample every
30 minutes. The double digested plasmids were purified from a 0.7% agarose gel (run for
90 minutes and stained with ethidium bromide). Bands on the gel containing the digested
pET19b and the excised genes were cut out and purified using a gene-clean kit (MP
Biomedicals) following the kit’s protocol. The purified digested pET19b plasmid and
purified excised genes were analyzed by agarose gel electrophoresis.
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2.1.3 Ligations
Each of the three genes (ml1682, ml2698, and rv3908) was ligated separately into
digested pET19b. A 1:1 ratio of plasmid:gene is theoretically ideal so ligations were set
up spanning a range around this 1:1 ratio (see Tables IV-VI). Ligations contained
digested plasmid, digested gene, ligase buffer, and ligase (Invitrogen), and were
incubated at 15 °C for approximately 24 hours.

Table IV: Ligation of ml1682 into pET19b.
Ligation pET19b:ml1682
pET19ba
ml1682b
Number of
Mixture
(ng)
(ng)
Coloniesc
A
75
0
~83
B
1:0.5
75
7.0
~362
C
1:1
75
13.5
~256
D
1:1.67
75
22.5
~94
a
: pET19b is 5705 basepairs
b
: ml1682 is 993 basepairs
c
: 50 mL transformation cell cultures plated onto plates containing LB-Ampicillin

Table V: Ligation of ml2698 into pET19b.
Ligation
Mixture
A
B
C
D

pET19b:ml2698
1 : 0.5
1 : 1.0
1: 2.2

pET19ba
(ng)
75
75
75
75

ml2698b
(ng)
0
5.1
10.2
22.4

a

Number of
Coloniesc
7
5
12
9

	
  
	
  

: pET19b is 5705 basepairs
: ml1682 is 747 basepairs
c
: 50 mL transformation cell cultures plated onto plates containing LB-Ampicillin
b
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Table VI: Ligation of rv3908 into pET19b.	
  
	
  
Ligation pET19b:rv3908a
pET19bb
rv3908c
Number of
Mixture
(ng)
(ng)
Coloniesd
A
75
0
88
B
1 : 0.15
75
1.5
53
C
1 : 0.30
75
3.0
20
D
1: 0.69
75
6.8
4
a
: the yield of purified excised gene was too low for a 1:1 ratio.
b
:pET19b is 5705 basepairs
c
: rv3908 is 747 basepairs
d
: 50 mL transformation cell cultures plated onto plates containing LB-Ampicillin
	
  
2.1.4 Transformations
5 µL of each Ligation mixture (A-D) were added to 50 µL E.coli DH5α (Novagen)
competent cells separately. pUC19 was added to the DH5α cells as a positive
transformation control. Samples were incubated on ice for 30 minutes, heat shocked in a
37 °C water bath for 25 seconds, and immediately placed back on ice for at least
2 minutes. 1 mL of LB media was added to each of the samples and were incubated at
37 °C for 1 hour with mixing every ~10 minutes. The cells were plated onto LB plates
containing 0.1 mg/mL ampicillin and incubated at 37 °C for approximately 16 hours.
Colonies were selected to analyze for the successful subcloning of pET19ml1682,
pET19ml2698, or pET19rv3908. Colonies containing pET19ml1682, pET19ml2698, or
pET19rv3908 were streaked out to single colonies and cell cultures were grown in LB
media containing 0.1 mg/mL ampicillin at 37 °C until ~1.0-1.5 ODs (A600) from these
single colonies. Freezer stocks of E. coli DH5α containing either pET19ml1682,
pET19ml2698, or pET19rv3908 were made using these cell cultures and glycerol and
stored at -80 °C.
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2.1.5 Plasmid Minipreps
12-24 different cultures containing a single colony from plates B-D (Table I-III)
were grown separately in 5 mL LB media containing 0.1 mg/mL ampicillin at 37 °C with
shaking for approximately 16 hours. The cells were harvested by centrifugation at
14,000 RCF at 4 °C for 2 minutes. Harvested cells were resuspended with solution I,
ruptured with solution II, and E. coli chromosomal DNA was precipitated with solution
III (as above in the midiprep procedure). Phenol:chloroform (1:1) followed by
chloroform extractions were performed (as above). The plasmid DNA was precipitated
with 70% ethanol by freezing and centrifuging (as above). The pellets were rinsed with
70% ice-cold ethanol, dried by vacuum centrifugation, and resuspended in sterile TE
buffer (10 mM Tris•HCl (pH 8.0), 1 mM EDTA) containing 20 µg/mL DNase-free
bovine pancreatic RNase A (Sigma). The plasmids were analyzed by 0.7% agarose gel
electrophoresis; the size of the purified plasmids were compared to purified pET19b to
determine if they potentially contained the gene of interest.

2.1.6 Verification of Recombinant Plasmids
To confirm that the isolated purified plasmids were recombinant pET19ml1682 (or
pET19ml2698 or pET19rv3908), two restriction enzyme digestions were carried out.
First, 8 µL of purified plasmids were digested with 1 µL each of NdeI and BamHI-HF
endonucleases (NEB). Second, 8 µL purified plasmids were digested with 2 µL EcoRV
endonuclease (NEB). The first method would excise the genes from the plasmid. The
second method would cut the plasmids in two locations to yield a 4229 bp fragment and a
fragment of 1488 bp for pET19b or larger if a gene was within the fragment. Digestions
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were carried out at 37 °C for one hour. All digestions were verified by agarose gel
electrophoresis.
E.coli BLR(DE3) (Novagen) competent cells were transformed with purified
pET19ml1682 (or pET19ml2698 or pET19rv3908). The transformed cells were plated
onto plates containing LB and 0.1 mg/mL ampicillin. Colonies were streaked to single
colonies. E. coli BLR(DE3) containing either pET19ml1682 (or pET19ml2698 or
pET19rv3908) were used to produce cell cultures by incubating them in LB media
containing 0.1 mg/mL ampicillin at 37 °C until 1.0 -1.5 OD (A600). Freezer stocks were
made from these cell cultures and glycerol and stored at -80 °C.
	
  

2.2 Overexpression and Purification of the Ml1682(HT), Ml2698(HT), and
Rv3908(HT) Proteins
2.2.1 100 mL Overexpression of Ml1682(HT) in E.coli BLR(DE3) at 37 °C
An inoculum of pET19ml1682 in E.coli BLR(DE3) was made by adding a scraping
of the freezer stock to 7.5 mL LB media containing 0.1 mg/mL ampicillin. The cells were
grown at 37 °C with shaking until it reached ~1.0-1.5 OD (A600). 5 mL of inoculum was
added to prewarmed 100 mL LB, containing 0.1 mg/mL ampicillin, and incubated at
37 °C with shaking. The cell density was analyzed every 30 minutes until it reached an
OD of 0.8 at A600 using UV-Vis spectrophotometry. The culture was induced with 1 mM
IPTG. Prior to induction, 1.5 mL culture was harvested and its pellet was labeled as time
point 0 (TP=0) and stored at -80 °C for protein gel analysis. The induced cells were
incubated at 37 °C with shaking for an additional 3 hours. Every 30 minutes, cell density
was determined at A600 and every hour, 1.5 mL of culture was harvested; pellets were
labeled as TP=1, 2, or 3 for 1, 2, or 3 hour(s) after induction, respectively, and were
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stored at -80 °C. After 3 hours, the cells were harvested by centrifugation at 3,000 RCF at
4 °C for 15 minutes. The pellet was suspended with ~20 mL buffered saline (50 mM
Tris•HCl (pH 7.5), 86 mM NaCl, 67 mM KCl). The suspension was centrifuged at 3,000
RCF at 4 °C for 15 minutes, and the pellet was rinsed with ~20 mL buffered saline. The
final pellet was stored at -80 °C.

2.2.2 100 mL Overexpression of Ml1682(HT), Ml2698(HT), and Rv3908(HT) in E.coli
BLR(DE3) at 15 °C
Inoculums of either pET19ml1682, pET19ml2698, or pET19rv3908 in E. coli
BLR(DE3) were made by adding a scraping of the freezer stock to 7.5 mL LB media
containing 0.1 mg/mL ampicillin. The cells were grown at 37 °C with shaking until it
reached ~1.0-1.5 OD (A600). 5 mL of inoculum was added to prewarmed 100 mL LB,
containing 0.1 mg/mL ampicillin, and incubated at 37 °C with shaking. The cell density
was analyzed every 30 minutes until it reached an OD of ~0.3 at A600, at which point the
cultures were incubated at 15 °C with shaking to an OD of ~0.6. Once the cell density
reached ~0.6 OD, the cultures were induced with 1 mM IPTG. Prior to induction, 1.5 mL
culture

was

harvested

and

its

pellet

was

labeled

TP=0

and

stored

at

-80 °C. The induced cells were incubated at 15 °C with shaking for an additional
22-24 hours. After 22-24 hours, 1.5 mL culture was harvested (TP=22-24). The rest of
the culture was harvested by centrifugation at 3,000 RCF at 4 °C for 15 minutes. The
pellets were resuspended in cold buffered saline (50 mM Tris•HCl (pH 7.5), 86 mM
NaCl, 67 mM KCl), recentrifuged at 3,000 RCF at 4 °C for 15 minutes, and the pellets
were rinsed with cold buffered saline. The final pellets were stored at -80 °C.
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2.2.3 2L Overexpression of Ml1682(HT), Ml2698(HT) and Rv3908(HT) in E.coli
BLR(DE3) at 15 °C
Inoculums of either pET19ml1682, pET19ml2698, or pET19rv3908 in E. coli
BLR(DE3) were made by adding a scraping of the freezer stock to 7.5 mL LB media
containing 0.1 mg/mL ampicillin. The cells were grown at 37 °C with shaking until it
reached ~1.0-1.5 OD (A600). 5 mL of inoculum was added to prewarmed 100 mL LB,
containing 0.1 mg/mL ampicillin, and incubated at 37 °C with shaking to a cell density of
~1 OD (A600). To each of two 1 L LB media containing 0.1 mg/mL ampicillin, 40 mL of
this inoculum was added. The cell density was analyzed every 30 minutes until it reached
an OD of ~0.3 at A600, at which point the cultures were incubated at 15 °C with shaking
to an OD of ~0.6. Once the cell density reached ~0.6 OD, the cultures were each induced
with 1 mM IPTG. Prior to induction, 1.5 mL of culture was harvested and its pellet was
labeled TP=0 and stored at -80 °C. The induced cells were incubated at 15 °C with
shaking for an additional 22-24 hours. After 22-24 hours, 1.5 mL culture was harvested
(TP=22-24). The rest of the culture was harvested by centrifugation at 3,000 RCF at 4 °C
for 15 minutes. The pellets were resuspended in cold buffered saline (50 mM Tris•HCl
(pH 7.5), 86 mM NaCl, 67 mM KCl), recentrifuged at 3,000 RCF at 4 °C for 15 minutes,
and the pellets were rinsed with cold buffered saline. The final pellets were stored at -80
°C.

2.2.4 Sonication
The pellets from the 100 mL overexpression cultures were resuspended in 1 mL
20 mM Tris•HCl (pH 8.0) while the pellets from the 2 L overexpression cultures were
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resuspended in 2 volumes (by weight) 20 mM Tris•HCl (pH 8.0). The suspended cells
were placed back at -80 °C for at least one hour to assist in cell lysis. 50 µl suspensions
were labeled as whole cell crude extract and saved for SDS PAGE analysis. Cells were
lysed by sonication using a Branson sonicator (output of 6.5 and 50% duty cycle), in 15second intervals for a total of 5 minutes. Sonicated samples were centrifuged at
14,000 RCF for 5 minutes (100 mL culture) or 10,000 RCF for 30 minutes (2 L culture).
The supernatants were separated from the pellets, and labeled as sonicated supernatant or
sonicated pellet, respectively. Pellets were resuspended in 1 mL (100 mL culture) or
2 volumes (2 L culture) of 20 mM Tris•HCl (pH 8.0). All fractions (whole cell crude
extract, sonicated supernatant, and sonicated pellet) were stored at -80 °C.

2.2.5 SDS-PAGE Analysis
All time points (TP=0, 1, 2, or 3 for overexpression at 37 °C; TP=0 or ~22-24 for
overexpression at 15 °C) were resuspended in H2O (100 µL per OD). Each whole cell
crude extract, sonicated supernatant, and sonicated pellet was diluted to 0.1x with 20 mM
Tris•HCl (pH 8.0). 5 µL of each time point and 0.1x sample, 10 µL 20 mM Tris•HCl
(pH 8.0), and 5 µL 4x protein loading buffer (200 mM Tris•HCl (pH 6.8), 40% glycerol,
8% SDS, 400 mM DTT, and 0.08% bromophenol blue dye) were mixed together and
boiled for 10 minutes. The samples were analyzed by SDS-PAGE (100 V for 20 minutes
followed by 300 V for ~30-35 minutes). The gel was stained with Coomassie blue, and
de-stained with solution I (45% methanol, 9% acetic acid) for ~10 minutes and solution II
(10% methanol and 10% acetic acid) overnight. The gel was placed in drying solution
(30% methanol and 5% glycerol) for 1 hour, and dried between cellophane membranes.
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2.2.6 Ni2+ Affinity Chromatography Purification for 100 mL Overexpression Cultures
1 mL Ni2+ affinity resin suspension (Novagen) was added to an “Econo” column
(Biorad) and rinsed with ~20 mL binding buffer (5 mM imidazole, 20 mM Tris•HCl
(pH 8.0), 0.5 M NaCl). The sonicated supernatant was added to the top of the column and
15 mL wash buffer (60 mM imidazole, 20 mM Tris•HCl (pH 8.0), 0.5 M NaCl) was used
to elute all of the E. coli proteins, leaving the His•Tagged protein (Ml1682(HT),
Ml2698(HT), or Rv3908(HT)) bound to the resin. The column was rinsed with 10 mL
elution buffer (250 mM imidazole, 20 mM Tris•HCl (pH 8.0), 0.5 M NaCl) to elute 1 mL
fractions containing the His•Tagged proteins. The protein concentration of each fraction
was determined by Bradford assays and the fractions containing protein were analyzed by
SDS PAGE.

2.2.7 Ni2+ Affinity Chromatography Purification for 2 L Overexpression Cultures
20 mL Ni2+ affinity resin suspension was added to a column (Biorad) and rinsed with
~200 mL binding buffer, the sonicated supernatant was added to the top of the column,
and 100 mL wash buffer was used to elute all of the E. coli proteins, leaving the
His•Tagged proteins bound to the resin. The column was rinsed with 50 mL of elution
buffer to elute 2 mL fractions containing the His•Tagged proteins. The protein
concentration of each fraction was determined by Bradford assays and the fractions
containing protein were analyzed by SDS PAGE.
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2.2.8 Dialysis and Concentration
Fractions containing the His•Tagged protein were combined and dialyzed using a
Slide-A-Lyzer (10 kD MWCO) cassette (Pierce). A “step down” dialysis procedure was
used: dialysis in buffer 1 (100 mM imidazole, 250 mM NaCl, 20 mM Tris•HCl (pH 8.0),
10% ammonium sulfate), followed by buffer 2 (50 mM imidazole, 100 mM NaCl,
20 mM Tris•HCl (pH 8.0), 10% ammonium sulfate), followed by buffer 3 (50 mM NaCl,
20 mM Tris•HCl (pH 8.0), 10% ammonium sulfate) each for 1 hour and finally buffer 4
(50 mM NaCl, 50 mM Tris•HCl (pH 7.5), 1 mM EDTA, 0.1 mM DTT, 10% ammonium
sulfate,) for 2 hours. The dialyzed protein solutions were concentrated using Amicon
Ultra Centrifugal filter units (Millipore) centrifuged at 4,000 RCF until the final volume
was ~0.5-1.0 mL.

2.3 Solubility Studies
2.3.1 Overexpression of Ml1682 and Ml1682(HT) in E.coli BLR(DE3) at 10 °C
The procedure was similar to the 100 mL overexpression of Ml1682(HT) in E.coli
BLR(DE3) at 15 °C with the following modification: once the culture reached ~0.4 OD,
it was placed at 10 °C with shaking for ~24 hours.

2.3.2 Overexpression of Ml1682(HT) Induced with Different Concentrations of IPTG
The procedure was similar to the 100 mL overexpression of Ml1682(HT) in E.coli
BLR(DE3) at 15 °C with the following modification: once cultures reached ~0.6 OD, one
culture was induced with 1 mM IPTG and the other culture was induced with 0.1 mM
IPTG.
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2.3.3 Overexpression of Ml1682(HT), Varying Incubation Time After Induction
1 L LB cultures were grown at 15 °C following the same procedure for 2 L
overexpression

of

Ml1682(HT)

with

the

following

modification:

instead

of

overexpression after induction for ~24 hours, the cells were grown for 5 hours after
induction. Prior to induction, 1.5 mL culture was harvested for TP=0 sample and 100 mL
culture was harvested. Every hour after induction with 1 mM IPTG, 1.5 mL culture
(TP=1, 2, 3, 4, and 5) and 100 mL culture was harvested. The 100 mL culture fractions
were resuspended in Tris•HCl (pH 8.0), sonicated, and fractionated.

2.3.4 Overexpression of Ml1682 and Ml1682(HT), Using the Chaperone GroESL
pGroESL plasmid was purified from E. coli HB101 using the miniprep procedure
detailed in section 2.1.5. A double transformation was performed by adding both
pGroESL and pETml1682 or pET19ml1682 to E. coli BLR(DE3) competent cells.
Ml1682 and Ml1682(HT) were overexpressed at 15 °C in the presence of the molecular
chaperone GroESL.
	
  
2.3.5 Overexpression of Ml1682 and Ml1682(HT) in E. coli Rosetta(DE3)
	
  Rosetta(DE3) cells were made competent using the CaCl2 method as described in
“Molecular

Cloning,

a

laboratory

manual.”60

50

mL

prewarmed

LB

with

chloramphenicol was inoculated with 5 mL Rosetta(DE3) overnight culture. The cells
were grown at 37 °C with shaking to an OD600 of ~0.4-0.6. The cells were harvested by
centrifugation at 4,000 RCF at 4 °C for 10 minutes. The pellet was resuspended in 25 mL
ice-cold 50 mM CaCl2 / 10 mM Tris•HCl (pH 8.0) and centrifuged at 4,000 RCF at 4 °C
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for 15 minutes. The pellets were resuspended in 50 mM CaCl2 / 10 mM Tris•HCl (pH
8.0) / 15% glycerol and divided into 200 µL aliquots. Samples were stored at 4 °C for
~18 hours. After ~18 hours, the cells were resuspended gently, quickly frozen in a dry ice
ethanol bath, and stored at -80 °C.
Rosetta(DE3)

competent

cells

were

transformed

with

pETml1682

and

pET19ml1682. Overexpression of Ml1682 and Ml1682(HT) in Rosetta(DE3) cells was
similar to the 100 mL overexpression of Ml1682(HT) in BLR(DE3) at 15 °C as described
in the section 2.2.2.

2.3.6 Overexpression of Ml1682 and Ml1682(HT) in Minimal Media
Ml1682 and Ml1682(HT) were overexpressed in minimal media. pET19b in E. coli
BLR(DE3) was used as a negative control. The procedure was similar to the 100 mL
overexpression of Ml1682(HT) at 37 °C (section 2.2.1), but minimal media was used
instead of LB media. Minimal media contained 200 mM sodium hydrogen phosphate,
110 mM potassium dihydrogen phosphate, 43 mM sodium chloride, 1 M magnesium
sulfate, 1 M calcium chloride, 20% glucose, 4.7 M ammonium chloride, and 0.1 mg/mL
ampicillin.

2.3.7 Overexpression of Ml1682(HT) in the Presence of Glycylglycine
Three different experiments were carried out using glycylglycine: 1) 100 mL LB
containing 500 mM glycylglycine was autoclaved. 2) 6.6 grams glycylglycine (500 mM)
was added to 100 mL LB just prior to inoculation. 3) 6.6 grams of glycylglycine
(500 mM) was added to 100 mL culture just prior to induction with IPTG. In all three
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experiments, Ml1682(HT) was overexpressed in E. coli BLR(DE3) at 15 °C as described
in section 2.2.2.
	
  

2.4 Characterization of Enzymes
2.4.1 Bradford Assay
1-20 µL solution containing protein was added to 800 µL water and mixed well. To
this, 200 µL Bradford dye (BioRad) was added. Protein concentration was determined by
measuring A595 and using the standard curve shown in Fig. 34 (Appendix).

2.4.2 Enzyme Assay
Reactions with different enzyme concentrations were carried out using 50 µL of a
standard reaction mixture containing 2 mM Ap4A, 5 mM MgCl2, 1 mM DTT, 50 mM
Tris•HCl (pH 9) and 0.057 U/µL calf intestinal alkaline phosphatase (BioLabs) to release
free phosphate. Reactions were incubated at 37 °C for 30 minutes and quenched with
250 µL 2 mM EDTA. 700 µL Ames mix (6:1 0.42% ammonium molybdate in 1 N
H2SO4 :	
   10% ascorbic acid) was added before incubation at 42 °C for 20 minutes to
produce a blue molybdophosphate complex. Phosphate was quantified by measuring A780
where 50 nmol phosphate will yield 1 OD.
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3. Results and Discussion
3.1 Subcloning of pET19ml1682, pET19ml2698, and pET19rv3908
3.1.1 Plasmid Purification
The pETml1682, pETml2698, pETrv3908 and three samples of pET19b plasmids
were purified from E.coli DH5α to yield DNA of sufficient quantity (see Table VII) and
quality (see Fig. 10). DNA concentrations were determined by:
[𝐃𝐍𝐀]  

𝐧𝐠
𝛍𝐋

=

𝐀 𝟐𝟔𝟎 (𝐎𝐃)×𝟓𝟎(

𝛍𝐠
)
𝐦𝐋

Eq. 13

𝐃𝐢𝐥𝐮𝐭𝐢𝐨𝐧  𝐅𝐚𝐜𝐭𝐨𝐫

Table VII: Quantification of pETml1682, pETml2698, pETrv3908, and pET19b.
Plasmid

	
  

[DNA]

Volume

DNA

(ng/µL)

(µL)

(µg)

pETml1682 170

120

20.4

pET19b

270

120

32.4

pETml2698 150

120

18.0

pET19b

140

120

16.8

pETrv3908

215

120

25.8

pET19b

255

120

30.6
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A.

B.

Figure 10: Agarose gel analysis of purified pET19b, pETml1682, and pETrv3908.
A. pET19b and pETml1682, Lane 1: λ HindIII MWMs; Lane 2: 100 ng pET19b; Lane 3:
100 ng pETml1682. B. pET19b and pETrv3908, Lane 1: λ HindIII MWMs; Lane 2: 100
ng pET19b; Lane 3: 100 ng pETrv3908; Lane 4: λ HindIII MWMs.

3.1.2 Restriction Enzyme Digests
The pETml1682, pETml2698, pETrv3908 and pET19b plasmids were each digested
with NdeI and BamHI-HF restriction enzymes. Single digests of pET19b by either NdeI
or BamHI-HF endonucleases indicated that both enzyme digestions were complete within
1 hour (see Fig. 11).
A.

B.

C.

Figure 11: Digestion of pET19b with NdeI and BamHI-HF endonucleases. A. Used for
ml1682 subcloning. B. Used for ml2698 subcloning. C. Used for rv3908 subcloning. For
all: Lane 1: λ HindIII MWMs; Lane 2: pET19b digested with NdeI; Lane 3: pET19b
digested with BamHI-HF; Lane 4: λ HindIII MWMs.
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3.1.3 Purification of Digested Plasmid and Excised Gene
In the restriction digests, the ml1682 gene was excised from pETml1682 and ran on
the gel as expected for DNA of 993 bp (Fig. 12A). The ml2698 gene was excised from
pETml2698 and ran on the gel as expected for DNA of 747 bp (Fig. 12B). The rv3908
gene was excised from pETrv3908 and ran on the gel as expected for DNA of 747 bp
(Fig. 12C). Due to technical issues, we were unable to take a photo of the gel; however, a
sketch is shown in Fig. 12C, and qualitatively, the gel looked similar to that in Fig. 12B
(for ml2698). Digested ml1682, ml2698, rv3908 and pET19b were extracted from the gel
and purified using the gene-clean kit.
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A.

B.

C.

Figure 12: Gel purification of digested ml1682, ml2698, rv3908, and pET19b. A. ml1682:
Lanes 1 and 6: λ HindIII MWMs; Lanes 2 and 3: digested pETml1682; Lanes 4 and 5:
digested pET19b. B. ml2698: Lanes 1 and 6: λ HindIII MWMs; Lanes 2 and 3: digested
pETml2698; Lanes 4 and 5: digested pET19b. C. rv3908: Lanes 1 and 6: λ HindIII
MWMs; Lanes 2 and 3: digested pETrv3908; Lanes 4 and 5: digested pET19b. All were
digested with NdeI and BamHI-HF endonucleases. For all, the digested pET19b and the
excised gene were purified from the gel.

Purity and yield of each digested gene and digested pET19b were analyzed by	
  
agarose gel electrophoresis (Fig. 13A). In Fig. 13A, the concentration of digested pET19b
is ~25 ng/µL and the concentration of ml1682 is ~5-10 ng/µL. In Fig. 13B, the
concentration of digested pET19b is ~25 ng/µL and the concentration of ml2698 is
~6 ng/µL. In Fig. 13C, the concentration of digested pET19b is ~25 ng/µL and in
Fig. 13D, the concentration of rv3908 is 1.5 ng/µL.
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A.

B.

C.

D.

	
  
Figure 13: Digested pET19b and excised genes (ml1682, ml2698, and rv3908) after
purification from gels using the “gene-clean” kit. A. ml1682 and pET19b: Lanes 2 and 9:
λ HindIII MWMs; Lanes 3 and 6: 100 ng of pET19b; Lanes 4 and 5: 1 µL and 2 µL
digested, gel-purified ml1682, respectively; Lanes 7 and 8: 1 µL and 2 µL digested, gelpurified pET19b, respectively. B. ml2698 and pET19b: Lanes 2 and 9: λ HindIII MWMs;
Lanes 3 and 6: 100 ng of pET19b; Lanes 4 and 5: 1 µL and 2 µL digested, gel-purified
ml2698, respectively; Lanes 7 and 8: 1 µL and 2 µL digested, gel-purified pET19b,
respectively. C. rv3908 and pET19b: Lanes 2 and 9: λ HindIII MWMs; Lanes 3 and 6:
100 ng of pET19b; Lanes 4 and 5: 1 µL and 2 µL digested, gel-purified rv3908,
respectively; Lanes 7 and 8: 1 µL and 2 µL digested, gel-purified pET19b, respectively.
D. rv3908: λ HindIII MWMs; Lane 3: 100 ng pET19b; Lanes 4 and 5: 1 µL and 2 µL
digested, gel-purified rv3908, respectively. Gel “D” was done because the gene bands
could not be visualized in gel “C”.
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3.1.4 Ligations and Transformations
The molecular sizes of digested pET19b, ml1682, ml2698, and rv3908 are ~5.7 kbp,
~1 kbp, ~0.8 kbp, and ~0.8 kbp, respectively. For 75 ng pET19b, 13.5 ng ml1682 is
required for a 1:1 ratio (Table IV), for 75 ng pET19b, 10.2 ng ml2698 is required for a
1:1 ratio (Table V), and for 75 ng pET19b, 6.75 ng rv3908 gene is required to make a
1:0.69 ratio (Table VI). It was impossible to obtain a 1:1 ratio for rv3908 due to its low
concentration, and lowering the amount of pET19b would have lowered the likelihood of
ligation.
Ligation mixture A containing digested, gene-cleaned pET19b (but no digested,
gene-cleaned gene) was used as a negative ligation control; pUC19 was used as a positive
transformation control. As seen in Table IV, there were 3-4 times more colonies that
resulted from ligations of plasmid and gene than from plasmid alone. However, as seen in
Tables V and VI, transformation with ligation mixture A yielded as many colonies as the
ligations B-D containing both pET19b and gene, indicating that the double digestions
with NdeI and BamHI-HF were not 100% complete, with some of the plasmids digested
by only one restriction enzyme, allowing these complementary sticky ends to reanneal.
However, in each case, at least one colony for each subclone (pET19ml1682,
pET19ml2698, and pET19rv3908) was determined to contain the proper subcloned
plasmid.
Twelve colonies were analyzed for possible pET19ml1682 subclones, twenty-four
colonies were analyzed for possible pET19ml2698 subclones, and twenty-four colonies
were analyzed for possible pET19rv3908 subclones.
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pET19b is ~5.7 kbp and while pET19ml1682, pET19ml2698, and pET19rv3908 are
6.6 kbp, 6.4 kbp, and 6.4 kbp, respectively, and thus the subclones containing the genes
would run slower on an agarose gel. Of the twelve colonies, ten appear to contain
pET19ml1682 in Fig. 14A. Of the twenty-four colonies, two appear to contain
pET19ml2698 in Fig. 14B. Of the twenty-four colonies, one appears to contain
pET19rv3908.
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A.

B.

C.

Figure 14: Miniprepped DNA: subcloned pET19ml1682, pET19ml2698, and
pET19rv3908. A. pET19ml1682: Lanes 1 and 14: 100 ng pET19b; Lanes 2-13:
miniprepped DNA. Lanes 2-3, 5-8, and 10-13 contain successfully subcloned
pET19ml1682. B. pET19ml2698: Lanes 1, 14, 15, and 28: 100 ng pET19b; Lanes 2-13,
and 16-27: miniprepped DNA. Lanes 16 and 18 contain successfully subcloned
pET19ml2698 (boxed in red). C. pET19rv3908: Lane 1, 12, 13 and 24: 100 ng pET19b;
Lanes 2-11, 14-23: miniprepped DNA; Lane 18: contains successfully subcloned
pET19rv3908 (boxed in red). In B and C: most of the other lanes contained pET19b that
had religated; this would be due to less than 100% cleavage by NdeI and/or BamHI-HF
endonucleases.
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3.1.5 Verification of Subcloning
To verify that pET19ml1682 was subcloned, the purified plasmids were digested
with EcoRV endonuclease. EcoRV cleaves pET19b to produce 4229 bp and 1488 bp
fragments, whereas EcoRV cleaves pET19ml1682 to produce 4229 bp and 2319 bp
fragments. All ten purified plasmids that were tested yielded bands of the proper size for
pET19ml1682 (Fig. 15A), indicating success in subcloning pET19ml1682.
The two possible subclones of pET19ml2698 (colonies B4 and B6) were digested
with NdeI and BamHI-HF and separately with EcoRV. EcoRV cleaves pET19ml2698 to
produce 4229 bp and 2229 bp fragments (Fig. 15B), thus indicating that ml2698 has been
subcloned into pET19b to yield the sublone pET19ml2698. NdeI and BamHI-HF cleave
ml2698 from pET19ml2698 to produce 5706 bp and 752 bp fragments corresponding to
pET19b and ml2698, respectively (Fig. 15B).
Likewise, the possible subclone of pET19rv3908 (colony C4) yielded similar results
to those discussed above for pET19ml2698 as the genes of rv3908 and ml2698 are the
same size. These digests indicate that rv3908 has been subcloned into pET19b to yield
the subclone pET19rv3908.
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A.

B.

C.

Figure 15: Verification of the subcloning of pET19ml1682, pET19ml2698, and
pET19rv3908. A. pET19ml1682: Lanes 1 and 14: λ HindIII MWMs; Lanes 2 and 13:
150 ng pET19b digested with EroRV; Lanes 3-12: miniprepped pET19ml1682 digested
with EcoRV. B. pET19ml2698: Lanes 1 and 8: λ HindIII MWMs; Lane 2: 150 ng
pET19b digested with EcoRV; Lanes 3 and 4: miniprepped pET19ml2698 digested with
EcoRV; Lane 5: pET19b digested with NdeI and BamHI-HF; Lanes 6 and 7:
miniprepped pET19ml2698 digested with NdeI and BamHI-HF; C. pET19rv3908: Lanes
1 and 6: λ HindIII MWMs; Lane 2: 150 ng pET19b digested with EcoRV; Lane 3:
miniprepped pET19rv3908 digested with EcoRV; Lane 4: pET19b digested with NdeI
and BamHI-HF; Lane 5: miniprepped pET19rv3908 digested with NdeI and BamHI-HF.
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3.2 Ml1682(HT), Ml2698(HT) and Rv3908(HT) Overexpression and Protein
Purification
3.2.1 Overexpression of Ml1682(HT) in E.coli BLR(DE3) in 100 mL LB at 37 °C
Ml1682(HT) protein expressed well in E.coli BLR(DE3) at 37 °C but it was very
insoluble. Most of the Ml1682(HT) was in the sonicated pellet and very little was in the
sonicated supernatant (as seen in Fig. 16 and as observed with ApnAase enzyme assays of
the sonicated supernatant as compared to the sonicated supernatant of E. coli BLR(DE3)
containing pET19b).

Figure 16: Overexpression of Ml1682(HT) in E.coli BLR(DE3) at 37 °C in 100 mL LB
media. Lane 1: MWMs; Lane 2: prior to induction; Lane 3: 1 hour after induction;
Lane 4: 2 hours after induction; Lane 5: 3 hours after induction; Lane 6: whole cell crude
extract; Lane 7: sonicated supernatant; Lane 8: sonicated pellet. An arrow points to
Ml1682(HT).
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3.2.2 Solubility Studies
Due to the insolubility of Ml1682(HT), a variety of methods were used to try to
increase the solubility of Ml1682(HT), as seen in Table VIII. All methods were tested
using Bradford assays, SDS PAGE, and ApnAase enzyme assays.

Table VIII: Methods to increase protein solubility: A check mark indicates that the
method did increase protein solubility compared to the other methods but not by a
significant amount.
Methods

Ml1682(HT)
15 °C

Vary
37 °C

✔

Temperature
Vary
[IPTG]

10 °C

1 mM
0.1 mM

✔

0.01 mM

Incubation Time
1 hr

2 hrs

3 hrs

4 hrs

5 hrs

After Induction
Incorporate GroESL

Overexpressed at 15 °C

Rosetta(DE3)

Overexpressed at 15 °C

Minimal Media

Overexpressed at 15 °C

Glycylglycine

Added

Added

Added

Prior to

Prior to

Prior to

Autoclaving

Inoculation

Induction

Lowering the temperature at which overexpression was achieved from 37 °C to
15 °C did improve the solubility of Ml1682(HT) (compare Fig. 16 to Fig. 17A). While it
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may be difficult to see the difference by SDS PAGE, the sonicated supernatant from the
15 °C overexpression had ~25% more ApnAase activity than the sonicated supernatant
from the 37 °C overexpression. Therefore we decided to test overexpression at 10 °C, but
saw very little difference in solubility of Ml1682(HT) between overexpression at 10 °C
vs. 15 °C (compare Fig. 17A and 17B). Since there was more expressed protein at 15 °C,
than at 10 °C, all other experiments were carried out using 15 °C as the temperature for
overexpression.
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A.	
  

	
  

	
  
B.

Figure 17: Overexpression of Ml1682(HT) in E.coli BLR(DE3) in 100 mL LB media at
varying temperatures. A. 15 °C: Lane 1: MWMs; Lane 2: prior to induction; Lane 3:
20 hours after induction; Lane 4: whole cell crude extract; Lane 5: freeze thaw extract;
Lane 6: sonicated supernatant; Lane 7: sonicated pellet. B. 10 °C: Lane 1: MWMs;
Lane 2: prior to induction; Lane 3: 22 hour after induction; Lane 4: sonicated supernatant;
Lane 5: sonicated pellet; Lane 6: whole cell crude extract; Lane 7: freeze thaw extract.
An arrow points to Ml1682(HT).

Lowering the concentration of IPTG did not increase the solubility of Ml1682(HT)
(Fig. 18). Therefore all other experiments were carried out using 1 mM IPTG for
induction of overexpression.
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Figure 18: Overexpression of Ml1682(HT) in E.coli BLR(DE3) at with varying IPTG
concentrations. Lane 1: MWMs; Lane 2-4: induction with 0.1 mM IPTG. Lane 2: whole
cell crude extract; Lane 3: sonicated supernatant; Lane 4: sonicated pellet; Lane 5-7:
induction with 0.01 mM IPTG. Lane 5: whole cell crude extract; Lane 6: sonicated
supernatant; Lane 7: sonicated pellet. An arrow points to Ml1682(HT).

Shortening the time for overexpression after induction with IPTG from ~22-24 hours
to five hours or less did not increase Ml1682(HT) solubility but did decrease expression.
Only samples from 3-5 hours after induction are shown in Fig. 19, however samples for 1
and 2 hours after induction did not contain any more soluble Ml1682(HT).
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Figure 19: Overexpression of Ml1682(HT) in E.coli BLR(DE3) at 15 °C varying
expression time after induction. Lane 1: MWMs; Lanes 2-4: 3 hours after induction with
IPTG. Lane 2: whole cell crude extract; Lane 3: sonicated supernatant; Lane 4: sonicated
pellet; Lanes 5-7: 4 hours after induction with IPTG. Lane 5: whole cell crude extract;
Lane 6: sonicated supernatant; Lane 7: sonicated pellet; Lane 8-10: 5 hours after
induction with IPTG. Lane 8: whole cell crude extract; Lane 9: sonicated supernatant;
Lane 10: sonicated pellet. An arrow points to Ml1682(HT).
	
  
Ml1682(HT) overexpressed in the presence of overexpressed chaperone did not
increase the solubility of Ml1682(HT) (Fig. 20A). Overexpression of Ml1682(HT) in the
E. coli Rosetta(DE3) strain (containing tRNAs for rare codons) also did not increase the
solubility of Ml1682(HT) (Fig. 20 B).
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A.

	
  
B.

	
  
Figure 20: Use of the chaperone GroESL and E. coli Rosetta(DE3) (codes for tRNAs for
rare codons).	
   A. Overexpression of Ml1682(HT) in E.coli BLR(DE3) with GroESL.
Lane 1: MWMs; Lane 2: prior to induction; Lane 3: 24 hours after induction; Lane 4:
whole cell crude extract; Lane 5: sonicated supernatant; Lane 6: sonicated pellet.
B. Overexpression of Ml1682(HT) in E. coli Rosetta(DE3). Lane 1: MWMs; Lane 2:
prior to induction; Lane 3: 23 hours after induction; Lane 4: whole cell crude extract;
Lane 5: sonicated supernatant; Lane 6: sonicated pellet. An arrow points to Ml1682(HT).	
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Another method that can slow down cell culture growth and thus allow proteins to
fold properly so they are soluble is to grow the cells in minimal media. However,
overexpression in minimal media did not increase the solubility of Ml1682(HT) (Fig. 21).

Figure 21:	
   Overexpression of Ml1682 and Ml1682(HT) in E.coli BLR(DE3) in minimal
media. Lane 1: MWMs; Lane 2-4: pET19b. Lane 2: whole cell crude extract; Lane 3:
sonicated supernatant; Lane 4: sonicated pellet; Lane 5-7: Ml1682(HT). Lane 5: whole
cell crude extract; Lane 6: sonicated supernatant; Lane 7: sonicated pellet; Lane 8-10:
Ml1682. Lane 8: whole cell crude extract; Lane 9: sonicated supernatant; Lane 10:
sonicated pellet. An arrow points to Ml1682 and Ml1682(HT).
	
  
Studies have shown that adding glycylglycine to rich media could increase protein
solubility for some proteins. In all three experiments using glycylglycine, Ml1682(HT)
was equally insoluble, thus for this protein, glycylglycine does not help Ml1682(HT) to
be more soluble (see Fig. 22)
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A.

B.

C.

Figure 22:	
  Effect of glycylglycine on protein solubility. Overexpression of Ml1682(HT)
in E.coli BLR(DE3). A. Glycylglycine was added to LB media prior to autoclaving.
B. Glycylglycine was added to LB media just prior to inoculation. C. Glycylglycine was
added to LB media just prior to induction. For all, Lane 1: MWMs; Lane 2: prior to
induction; Lane 3: ~24 hours after induction; Lane 4: whole cell crude extract; Lane 5:
sonicated supernatant; Lane 6: sonicated pellet; Lane 7: prior to induction. An arrow
points to Ml1682(HT).
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None of the methods that we explored increased the solubility of Ml1682 or
Ml1682(HT). Upon further reading of the literature, it appears that expression of soluble
M. leprae proteins can be challenging.
Another method that we did not try was to add a solubility tag to the protein. 1) This
would have required further subcloning, which we did not have time to do and 2) We
have not had success with solubility tags including the use of the maltose binding protein,
which yielded a soluble but misfolded ApnAase from Legionella pneumophila. We will
certainly further investigate other methods to attempt to express soluble Ml1682 and
Ml1682(HT). It is preferential to express soluble protein vs. solubilizing insoluble protein
because it is not known if activity is lost in the process of solubilization.

3.2.3 2 L Overexpression of Ml1682(HT) in E.coli BLR(DE3) at 15 °C
The overexpression of Ml1682(HT) in E. coli BLR(DE3) was scaled up to 2 L (two
1 L cultures) to generate enough protein to purify. The expression and solubility of
Ml1682(HT) was comparable to the 100 mL culture, as seen in Fig. 23.
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Figure 23: Overexpression of Ml1682(HT) in E.coli BLR(DE3) cells at 15 °C in 1 L LB
media. Lane 1: MWMs; Lane 2: prior to induction; Lane 3: 22 hour after induction;
Lane 4: whole cell crude extract; Lane 5: sonicated supernatant; Lane 6: sonicated pellet.
An arrow points to Ml1682(HT).

3.2.4 Purification of Ml1682(HT) in E.coli BLR(DE3)
After sonication of the harvested cells, the sonicated supernatant was fractionated by
Ni2+ affinity chromatography. All other proteins eluted from the column with the addition
of wash buffer, while the 35 kDa Ml1682(HT) protein did not elute until elution buffer
was added over the column (see Fig. 24). The Ni2+ affinity chromatography did isolate
purified Ml1682(HT); however, the protein concentration was too low to dialyze and
concentrate. By using Bradford assays, we determined that Ml1682(HT) was lost in the
dialysis process, probably through precipitation. Thus increasing Ml1682(HT) solubility
will be essential in order to purify the protein for characterization. 	
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Figure 24: Purification of Ml1682(HT) by Ni2+ affinity chromatography. Lane 1:
sonicated supernatant; Lanes 2 and 3: wash fractions 3 and 4; Lanes 4-9: elute fractions
4-7, 9, and 11 (Ml1682(HT) boxed in red); Lane 10: MWMs.
	
  
3.2.5 Overexpression and Purification of Ml2698(HT)
The overexpression and solubility of Ml2698(HT) was comparable with that of
Ml1682(HT) (compare Fig. 23 and 25). The 30 kDa Ml2698(HT) protein was also
purified readily from the other proteins in the sonicated supernatant via the Ni2+ affinity
chromatography (see Fig. 26).
However, there was even less soluble Ml2698(HT) protein that eluted from the Ni2+
column (see Fig. 26), and not enough to dialyze and concentrate.
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Figure 25: Overexpression of Ml2698(HT) in E.coli BLR(DE3) at 15 °C in 1 L LB
media. Lane 1: MWMs; Lane 2: Prior to induction; Lane 3: 22 hours after induction;
Lane 4: whole cell crude extract; Lane 5: sonicated supernatant; Lane 6: sonicated pellet.
An arrow points to Ml2698(HT).
	
  

Figure 26: Purification of Ml2698(HT) by Ni2+ affinity chromatography. Lane 1:
sonicated supernatant; Lanes 2-3: wash fractions 2-3; Lanes 4-9: elute fractions 3-7, and
10 (Ml2698(HT) boxed in red); Lane 10: MWMs.	
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3.2.6 Overexpression and Purification of Rv3908(HT)
Rv3908(HT) protein expressed well in E.coli BLR(DE3) at 15 °C and it was more
soluble than Ml1682(HT) or Ml2698(HT) as seen in Fig. 27. The 30 kDa Rv3908(HT)
protein also purified well from the other proteins over the Ni2+ affinity chromatography
column with significantly more pure Rv3908(HT) eluting from the column (Fig. 28).
However Rv3908(HT) precipitated during dialysis and thus we will need to
determine dialysis conditions for this protein.

Figure 27: Overexpression of Rv3908(HT) in E.coli BLR(DE3) at 15 °C in 1 L LB
media. Lane 1: MWMs; Lane 2: Prior to induction; Lane 3: 22 hours after induction;
Lane 4: whole cell crude extract; Lane 5: sonicated supernatant; Lane 6: sonicated pellet.
An arrow points to Rv3908(HT).
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Figure 28: Purification of Rv3908(HT) by Ni2+ affinity chromatography. Lane 1:
sonicated supernatant; Lanes 2-4: wash fractions 2-4; Lane 5-9: elute fractions 4, 6-7, and
11-12 (Rv3908(HT) boxed in red); Lane 10: MWMs.
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4. Conclusions
The genes ml1682, ml2698, and rv3908 have been subcloned into pET19b for
overexpression of His•Tagged proteins. Ml1682(HT), Ml2698(HT), and Rv3908(HT)
have been expressed and show ApnAase activity in the whole cell crude extract above
that of the negative control. Rv3908(HT) was relatively more soluble then either
Ml1682(HT) or Ml2698(HT), which were both very insoluble. Rv3908(HT) was purified
over a Ni2+ affinity column, but precipitated during dialysis following chromatography.
Future work will include determining dialysis conditions that will not precipitate
Rv3908(HT) followed by enzyme characterization. A variety of methods were used to try
to increase the solubility of Ml1682(HT), however Ml1682(HT) is still very insoluble.
Purification of Ml1682(HT) and Ml2698(HT) via Ni2+ affinity chromatography was
successful but yielded insufficient quantities of purified protein to be able to dialyze and
analyze; these proteins’ solubility will need to be increased for further purification and
characterization of these enzymes.
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7. Appendix
	
  

	
  
Figure 29: Leprosy classification: Lepromatous leprosy, Intermediate state, and
Tuberculoid leprosy. Intermediate state can be either borderline tuberculoid or borderline
lepromatous. Tuberculoid leprosy is usually stable and rarely contagious with symptoms
of hypopigmentation with loss of sensation. Whereas lepromatous leprosy is dynamic,
contagious, involves more severe disability and nerve damage. Tuberculoid leprosy can
easily turn into lepromatous leprosy if the immune system is not strong enough.
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Figure 30: Current antibiotics used to treat MTB, and their targets.
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Figure 31: The transmission cycle of MTB. A. Transmission stage: MTB has a nearly
impenetrable lipid-rich cell wall that enables it to survive in air droplets. Once inhaled,
MTB invades the pulmonary alveoli and is taken up by macrophages. MTB takes over
the cells’ internal machinery to prevent further internal phagocytic destruction and starts
to replicate. B. Immune response stage: The infected macrophages signal other immune
cells to attack MTB. C. Latency stage: In most people, the immune system is able to
confine the infection to granulomas, where it can be contained for years. D. Activation
stage: When the immune system cannot control the infection, the granulomas break
down, releasing MTB throughout the body.
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Figure 32: Throughout history, TB has killed more people than any other infectious
disease. Over a billion people have died from TB in last 200 years.
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Figure 33: Ni2+ affinity chromatography used to purify Histidine-tagged proteins.
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Figure 34: Standard curve for Bradford protein analysis. Using BSA standard.
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